Igm biosciences CFO Tahir Misbah sells $1,825 in stock

Published 21/06/2025, 01:26
Igm biosciences CFO Tahir Misbah sells $1,825 in stock

igm biosciences (NASDAQ:IGMS) Chief Financial Officer Misbah Tahir sold 1,522 shares of the company’s common stock on June 16, 2025. The sales were executed at prices ranging from $1.17 to $1.22, with a weighted average price of $1.1992, for a total transaction value of $1,825. The transaction comes as the stock has declined over 83% in the past six months, with the company’s market capitalization now at approximately $71 million. According to InvestingPro analysis, the stock is currently trading below its Fair Value.

Following the transaction, Tahir directly owns 178,802 shares of igm biosciences.

The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units.

In other recent news, IGM Biosciences, Inc. announced the termination of its collaboration and license agreement with Genzyme Corporation, a Sanofi (NASDAQ:SNY) entity. The agreement, which began on March 28, 2022, was focused on developing IgM antibodies for diseases like cancer and immunological disorders. The termination notice was received on May 5, 2025, and will take effect 30 days later. In response, IGM Biosciences has implemented an 80% reduction in its workforce and closed most of its laboratory and office spaces to cut operating costs. The company is now exploring strategic alternatives and reorganization options. These recent developments are expected to have significant implications for the company’s operations and financial health. The information related to this termination is not considered filed under the Securities Exchange Act of 1934 unless specifically referenced in future filings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.